101. FREQUENCY AND PROGNOSTIC IMPORTANCE OF TRANSLOCATION (6;9) (MYB-NFIB GENES) IN HEAD AND NECK ADENOID CYSTIC CARCINOMA: A SYSTEMATIC REVIEW
- Author
-
Sara Ferreira Dos Santos Costa, Albina Altemani, Pablo Agustin Vargas, Felipe Paiva Fonseca, Lucas Guimarães Abreu, Yasmin Dias De Almeida Pinto, and Bruno Augusto Benevenuto de Andrade
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Adenoid cystic carcinoma ,Incidence (epidemiology) ,Myb nfib ,Chromosomal translocation ,medicine.disease ,Pathology and Forensic Medicine ,Internal medicine ,Medicine ,Radiology, Nuclear Medicine and imaging ,Dentistry (miscellaneous) ,Surgery ,Oral Surgery ,Tumor location ,Best evidence ,business ,Head and neck ,Gene - Abstract
Objective To carry out a systematic review to address the prevalence and the prognostic potential of translocation (6;9) (MYB-NFIB genes) mutation in head and neck adenoid cystic carcinoma (AdCC). Study Design Articles published were retrieved from multiple databases using specific search strategies. They were screened and articles included had their data extracted by 2 authors who latter assessed the risk of bias of each study. Quantitative analysis was done to determine the incidence of the translocation. Results A total of 1107 articles were initially retrieved with 36 remaining for data extraction. The presence of t(6;9)(MYB-NFIB) translocation varied significantly, especially due to methodologic heterogeneity among studies. The meta-analysis revealed a range from 16% to 100% in the prevalence of the translocation. A total of 11 studies attempted to determine the prognostic importance of the mutation, but no study found any significant association with survival rates and only 3 studies observed a significant association with age, sex, tumor location, and the presence of recurrences and metastases. Conclusions The prevalence of t(6;9)(MYB-NFIB) translocation in head and neck AdCC varies according to the laboratory methods used and the best evidence available demonstrate that t(6;9)(MYB-NFIB) is not a prognostic determinant. Support: CNPq and FAPEMIG.
- Published
- 2020
- Full Text
- View/download PDF